Cancer-related Problem/Condition
Conditions
Keywords
Cancer pain, Magnesiun
Brief summary
This study is an evaluation of the analgesic effect of magnesium associated with morphine in patients with cancer pain.
Detailed description
The study is prospective, randomized, double-blind. The patients will be allocated into two groups. After approval by the Ethics Committee and signed informed consent, 40 patients, aged \> 18 years of both genders with cancer pain, will be studied. The patients in group 1 (n = 20) will receive a dose of magnesium sulfate (65 mg) po twice daily. Patients in Group 2 (n = 20) will receive placebo twice a day. The Mg and placebo capsules are identical. Everyone will receive morphine as needed. Will be recorded: tumor location, factors which worsen the pain, quality of pain. Pain intensity will be assessed by numerical scale from zero to 10 at T0 (first visit) and after 1, 2, 3. and 4wk. The patient will note the intensity of pain and side effects at home. Functional performance assessment will bes done by the Karnofsky Performance Status Scale. Quality of life will be assessed by the QLQ-c30.
Interventions
DRUGMagnesiun
75mg pills; each 12h; 12wk
Sponsors
Federal University of São Paulo
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* After approval by the Ethics Committee and signed informed consent, * 40 patients, \> 18 years, with cancer pain, and taking morphine (third step of the analgesic ladder recommended by WHO) were studied
Exclusion criteria
* Were excluded from the study patients with hypersensitivity to drugs and pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain relief | 12 wk |
Secondary
| Measure | Time frame |
|---|---|
| Morphine dose | 12 wk |
Countries
Brazil
Outcome results
None listed